Recent advancements focus on using chimeric autoantibody receptor T (CAAR-T) cells and CAR-T regulatory T cells (CAR-Tregs) to restore immune tolerance in conditions like pemphigus vulgaris (PV), a rare skin-blistering disease caused by autoantibodies against desmoglein 1 and 3 (DSG1/3) [42,43]; or to combat muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG), a life-threatening muscle disorder characterized by muscle weakness due to anti-MuSK autoantibodies [43,44,45] (Table 2). Here, DSG1 is linked to myasthenia gravis.